Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.
Cytokine Release Syndrome Treatment Market Revenue Growth On Track For A 13.3% CAGR Through 2030
The cytokine release syndrome treatment market has seen rapid growth in recent years. This market is expected to expand from $1.42 billion in 2025 to $1.61 billion in 2026, achieving a compound annual growth rate (CAGR) of 13.6%. The historical growth can be attributed to several factors, including the rise of advanced immunotherapy treatments, increased adoption of CAR-T cell therapy, the availability of corticosteroids for immune modulation, heightened clinical awareness of cytokine storms, and improvements in critical care infrastructure.
The cytokine release syndrome treatment market size is set to experience substantial growth in the upcoming years. It is projected to expand to $2.66 billion in 2030, driven by a compound annual growth rate (CAGR) of 13.3%. This expansion over the forecast period is attributable to the increasing utilization of next-generation immunotherapies, rising investments in cytokine modulation research, the expansion of oncology treatment centers, a growing emphasis on personalized immune management, and the development of novel anti-inflammatory biologics. Prominent trends for this period include the increased adoption of IL-6 and IL-1 targeted therapies, a rising uptake of monoclonal antibodies for CRS management, the broadening of hospital-based CRS treatment protocols, an expanding integration of early diagnostic monitoring, and enhanced supportive care management strategies.
Get A Free Sample Report With In-Depth Market Insights:
Cytokine Release Syndrome Treatment Market Industry Drivers: What’s Behind The Revenue Growth?
The rising adoption of cancer therapies is anticipated to fuel the expansion of the cytokine release syndrome (CRS) treatment market in the coming period. This increase in cancer treatments stems from a global rise in cancer cases and progress in diagnostic tools, leading to earlier diagnoses and a wider array of available therapies. Furthermore, better patient survival outcomes and broader access to healthcare services contribute to the escalating need for these treatments. Managing CRS involves providing supportive care, administering anti-cytokine drugs, and continuous patient monitoring to alleviate symptoms and reduce the inflammatory reactions induced by cancer therapies. As an illustration, data from May 2024 published by the National Health Service (NHS), a healthcare system in the UK, revealed that nearly 340,000 individuals initiated their first cancer treatment during the year spanning April 2023 to March 2024. Moreover, urgent referrals for suspected cancer reached an unprecedented level in March 2024, with 12,554 patients being seen daily, surpassing the earlier high of 12,376 patients per working day recorded in July 2023. Consequently, the expanding use of cancer treatments is propelling the cytokine release syndrome (CRS) treatment market.
Cytokine Release Syndrome Treatment Market Segment Landscape: Which Areas Lead Development?
The cytokine release syndrome treatment market covered in this report is segmented –
1) By Drug Type: Corticosteroids, Monoclonal Antibodies, Other Immunosuppressants
2) By Administration: Intravenous, Subcutaneous, Oral
3) By Application: Oncological Treatments, Autoimmune Disorders, Other Applications
4) By End User: Hospitals, Specialty Clinics, Home Care Settings
Subsegments:
1) Corticosteroids: Prednisone, Dexamethasone, Methylprednisolone
2) Monoclonal Antibodies: Tocilizumab (IL-6 Inhibitor), Siltuximab (IL-6 Inhibitor), Anakinra (IL-1 Receptor Antagonist)
3) Other Immunosuppressants: Janus Kinase (JAK) Inhibitors, Calcineurin Inhibitors, Tumor Necrosis Factor (TNF) Inhibitors
#Cytokine Release Syndrome Treatment Market Growth Trends: What’s Shaping The Future Outlook?
Prominent companies within the cytokine release syndrome treatment market are developing sophisticated drug delivery methods, such as intravenous infusion, to boost treatment accuracy, diminish side effects, and achieve better patient results. Intravenous infusion, when used for cytokine release syndrome, facilitates swift and precise drug delivery directly into the bloodstream, guaranteeing a quick therapeutic response. For instance, in September 2023, Chugai Pharmaceutical Co. Ltd., a pharmaceutical company based in Japan, secured regulatory clearance for Actemra (tocilizumab), which is a humanized anti-IL-6 receptor monoclonal antibody, from the Ministry of Health, Labor, and Welfare, a government authority also in Japan. This approval is designated for treating cytokine release syndrome (CRS) caused by various cancer therapies. Actemra Intravenous Infusion (available in 80 mg, 200 mg, and 400 mg doses) serves as an extended indication for addressing cytokine release syndrome (CRS) that originates from cancer therapy. With this updated indication, Actemra can now be utilized as an anti-cytokine therapy for CRS stemming from cancer treatments beyond specific tumor-targeting T-cell infusion therapy.
Cytokine Release Syndrome Treatment Market Industry Leaders And Competitive Landscape
Major companies operating in the cytokine release syndrome treatment market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche AG, Merck & Co. Inc., AbbVie Inc., Bayer AG, Sanofi S.A., Thermo Fisher Scientific Inc., Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Gilead Sciences Inc., Amgen Inc., Regeneron Pharmaceuticals Inc., Chugai Pharmaceutical Co. Ltd., Incyte Corporation, Swedish Orphan Biovitrum AB (publ), Bio-Techne Corporation, GenScript Biotech Corporation, Abcam plc, Applied Biological Materials Inc., Poolbeg Pharma, arigo Biolaboratories Corp., CytoAgents Inc, bluebird bio Inc.
View The Full Cytokine Release Syndrome Treatment Market Report:
Cytokine Release Syndrome Treatment Market Regional Distribution: Which Areas Power Market Growth?
North America was the largest region in the cytokine release syndrome treatment market in 2025. The regions covered in the cytokine release syndrome treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model